Abstract: Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.
Abstract: The invention provides a method of producing a highly stable pharmaceutical aerosol suspension formulation suitable for use in a metered dose inhaler, the formulation comprising formoterol fumarate di-hydrate in suspension, a steroid in suspension, a propellant and ethanol, the method comprising the steps of drying the formoterol fumarate di-hydrate to a water content of 4.8 to 4.28%.
Abstract: The present disclosure provides dry compositions and methods for using the dry compositions to treat animal facilities. In particular, a dry composition comprises an acid, which provides an immediate source of protons, and a process residue comprising alum and a material comprising reactive aluminum, each of which provides a delayed source of protons.
Abstract: A galenical form for the buccal transmucous administration of at least one active ingredient of the triptan family, includes at least: the active ingredient in basic form and in salt form, and a hydro-alcoholic solution that titrates at least 15 degrees of alcohol, whereby the active ingredient is present in a stable and complete state of dissolution in the hydro-alcoholic solution so as to allow a fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for the production of this galenical formulation as well as its use are described.
Abstract: The invention relates to co-crystals of metalaxyl and prothioconazole, to methods of making them, to compositions containing them and to the methods of using said co-crystals and said compositions to treat crops and plants.
Abstract: The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by a support appearing as granules. Said fluid may be CO2 or another solvent and the support, anhydrous lactose or mannitol. Application of the pharmaceutical composition in the cases when increased short term alertness and over a short period is required for the consumer of the pharmaceutical composition.
Abstract: The invention relates to a continuous method for producing inorganic or organic nanoparticles having multiple nuclei functionalised with proteins, using a T-type reactor that operates at high pressure, the primary particles that form the nuclei of the nanoparticles being smaller than 10 nm and said primary particles being immersed in a proteinaceous matrix that forms the nanoparticle in sizes of between 30 nm and 500 nm. The invention also relates to the nanoparticles produced by means of said method.
Abstract: A method enables photoplethysmograph measurement of volume status. The method includes the steps of converting photoplethysmograph voltages to volume measurements and characterizing a local microcirculation as a microcosm in a manner allowing a photoplethysmograph to facilitate noninvasive monitoring of systemic status.
Abstract: The present disclosure relates to a separable hard capsule for containing a medication. The capsule may be opened by finger force and used, for example, by pediatric and geriatric patients.
Type:
Grant
Filed:
February 13, 2014
Date of Patent:
October 3, 2017
Assignee:
Capsugel Belgium NV
Inventors:
Hilde Buydts, Stefaan Jaak Vanquickenborne
Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.
Abstract: The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20?m or less, or 10?m or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g., an alcohol, acetone, or acetonitrile) solvents. In the composition a maximum solubility for the macrolide that is greater than a maximum solubility of the macrolide dissolved in either the first or second solvent individually. The first and second solvents are then evaporated from the composition to provide the macrolide particulates. In another method, the particulates can be formed by a method including sonication and stirring/evaporation steps, and the particulates can be obtained from a supersaturated solution, formed during the process.
Type:
Grant
Filed:
June 12, 2014
Date of Patent:
September 26, 2017
Assignee:
SURMODICS, INC.
Inventors:
Joram Slager, Aleksey V. Kurdyumov, Toni M. Heyer
Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
September 5, 2017
Assignee:
Purdue Pharma L.P.
Inventors:
Benjamin Oshlack, Curtis Wright, Derek Prater
Abstract: The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.
Abstract: The invention provides cryogels whose porosity, pore size, pore connectivity, swelling agent concentration, and/or specific volume undergoes a change from a first value to a second value in response to an electrical stimulus. The cryogels have interconnected macropores which greatly enhance their ability to rapidly undergo volumetric collapse when subjected to moderate electric fields. The cryogels of the invention can be easily integrated into arrays capable of rapid configurational and chromatic optical modulations, and when loaded with drugs, are able to coordinate the delivery profile of multiple drugs. The cryogel can be prepared by polymerizing an aqueous solution of charged monomers and cross-linker monomers at a temperature below the freezing temperature of the solvent.
Type:
Grant
Filed:
August 2, 2013
Date of Patent:
July 18, 2017
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Stephen Michael Kennedy, Sidi Ahmed Bencherif, David J. Mooney
Abstract: The embodiments herein relate to a therapeutically active composition for the treatment, inhibition or attenuation of a virus. The composition comprises an effective amount of a sulfur containing compound along with one or more pharmaceutically acceptable carriers or excipients. The sulfur containing compound impairs a disulfide bond of a plurality of virus. The plurality of virus includes Ebola virus, herpes virus, dengue virus, smallpox virus, measles virus, mumps rubella virus, HIV (human immunodeficiency virus), Lassa fever virus and yellow fever virus, and even cancer, solid tumors, especially the fibrosarcoma tumor. The sulfur containing compound is sodium thiosulfate (Na2S2O3) (“STS”). The composition is given orally, intravenously, inhalation, intravesical, vaginal, rectal, sublingual, ophthalmic, or topical.
Abstract: The present invention relates to bath compositions that may release nitric oxide when combined with an aqueous solution, thereby producing a nitric oxide releasing soak and/or bath. The present invention also relates to methods of using nitric oxide releasing bath compositions.
Abstract: Compositions and therapeutic kits including an aerosol container containing a foamable composition that includes a nonsteroidal immunomodulating agent are described. The foamable composition includes a liquid hydrophobic carrier; a surface-active agent; polymeric additive; water; and a propellant.
Type:
Grant
Filed:
March 11, 2005
Date of Patent:
June 6, 2017
Assignee:
FOAMIX PHARMACEUTICALS LTD.
Inventors:
Dov Tamarkin, Meir Eini, Doron Friedman
Abstract: Provided are microcapsules containing a solid core including at least one essential oil mixed with a porous solid material, where this solid core is coated by at least one layer of a polyurea film and/or a polyurethane film or an amphipathic shell composed of a multivalent salt form of at least one alkanoic acid. Further provided are compositions including these microcapsules, and uses thereof in a variety of agricultural and environmental applications.
Type:
Grant
Filed:
August 11, 2009
Date of Patent:
May 23, 2017
Assignee:
BOTANOCAP LTD.
Inventors:
Arie Markus, Charles Linder, Pnina Strongin
Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
May 23, 2017
Assignee:
Purdue Pharma L.P.
Inventors:
Benjamin Oshlack, Curtis Wright, Derek Prater